OSCR

2-Phenyl-3-(Phenylselanyl)Benzofuran As a Promising Antidepressant Candidate: Mechanistic Insights Into Nitrergic Modulation and Subchronic Efficacy and Safety Profiling.

Overview

  1. Programa de Pós-Graduação em Bioquímica e Bioprospecção, Laboratório de Bioquímica e Neurofarmacologia Molecular (LABIONEM), Centro de Ciências Químicas, Farmacêuticas e de Alimentos (CCQFA), Universidade Federal de Pelotas (UFPel),CEP 96010-900 Pelotas, RS Brasil
  2. Instituto de Química, Universidade Federal de Goiás (UFG),Goiânia, GO CEP 74690‑900 Brasil
  3. Programa de Pós-Graduação em Química (PPGQ), Laboratório de Síntese Orgânica Limpa (LASOL), Centro de Ciências Químicas, Farmacêuticas e de Alimentos (CCQFA), Universidade Federal de Pelotas (UFPel),CEP 96010-900 Pelotas, RS Brasil
  4. Universidade Federal do Pampa (UNIPAMPA),CEP 97500-970 Uruguaiana, RS Brasil
Journal: Molecular neurobiology, volume 63, issue 1, article 771
Dates: received 31 January 2026; accepted 8 July 2026; published online 16 July 2026; in print 2026
Type: Research article · Language: English
License: CC BY
Identifiers: DOI 10.1007/s12035-026-06058-6 · PMID 42461353 · PMCID PMC13375843 · OpenAlex W7168890894
Open access: hybrid, a free copy (OpenAlex)
Categories: mouse (organism), depression (population)
Methods: Statistics, Connectivity
Keywords: SeBZF1, Antidepressant, NO-cGMP, Mice, Selenium, Tail suspension test
MeSH: Antidepressive Agents*, Benzofurans*, Nitric Oxide*, Animals, Cyclic GMP, Hindlimb Suspension, Male, Mice, Molecular Docking Simulation (* major topic)
Topic: Organoselenium and organotellurium chemistry (Organic Chemistry, Chemistry), according to OpenAlex
Funding: Coordination for the Improvement of Higher Education Personnel (438384/2018–0, 420386/2018–1); State of Rio Grande do Sul Research Support Foundation (21/2551-0000614-5–0, 21/2551-0000728-1); Universidade Federal de Pelotas
Citations: not cited yet (Europe PMC); 81 references in the paper

Abstract

The compound 2-phenyl-3-(phenylselanyl)benzofuran (SeBZF1), a selenium-containing molecule based on a benzofuran scaffold, has shown antidepressant-like effects. This study investigated the involvement of the nitric oxide (NO)-cyclic guanosine monophosphate (cGMP) pathway, the efficacy of subchronic treatment in male Swiss mice, and computational analyses. Acute SeBZF1 administration (50 mg/kg, i.g.) showed antidepressant-like effects in the tail suspension test (TST). These effects were reversed by pretreatment with L-arginine (a NO precursor, 750 mg/kg, intraperitoneal, i.p.) or sildenafil (a phosphodiesterase-5 inhibitor, 5 mg/kg, i.p.), suggesting NO-cGMP pathway involvement. A subeffective dose of SeBZF1 (1 mg/kg, i.g.) elicited synergistic antidepressant-like effects when combined with N(ω)-nitro-L-arginine methyl ester (L-NAME, a nitric oxide synthase (NOS) inhibitor, 10 mg/kg, i.p.) or 7-nitroindazole (a specific neuronal NOS inhibitor, 30 mg/kg, i.p.). Furthermore, methylene blue (an inhibitor of NOS and soluble guanylate cyclase (sGC), 10 mg/kg, i.p.) and 1H-[1,2,4]Oxadiazolo[4,3-a]quinoxalin-1-one (ODQ, a sGC inhibitor, 30 pmol/site, intracerebroventricular), both soluble guanylate cyclase (sGC) inhibitors, enhanced the subeffective SeBZF1 dose. Subchronic SeBZF1 treatment (1 mg/kg, i.g., for 35 days) significantly produced antidepressant-like action without causing weight loss or organ damage. Biochemical analysis revealed reduced nitrate/nitrite levels in the prefrontal cortex and hippocampus, indicating modulation of NO signaling. Molecular docking suggested interactions between SeBZF1 and NOS isoforms, while pharmacokinetic analysis suggested brain penetration and absence of overt toxicity. The present study concludes that SeBZF1 exhibits antidepressant-like effects through the NO–cGMP pathway, is effective at low subchronic doses, and displays favorable pharmacokinetic and safety profiles, supporting its potential as a novel antidepressant candidate.

Supplementary Information: The online version contains supplementary material available at 10.1007/s12035-026-06058-6.

Reproduced under the paper's license (CC BY), from the paper cited above.

Code

The paper links to its data and to no code of its authors: see the Data section.

Tracing map

A tracing map links a paper to the code its authors published: this paper has none, so it has no map.

Data

Datasets cited

Data Availability

The datasets generated and/or analyzed during the current study are available from the corresponding author upon request.

Reproduced under the paper's license (CC BY), from the paper cited above.

Versions

The history of this record: each version stored by the harvester or made by a correction of its authors or of the maintainers of its code, and what changed in its facts. The texts of the paper (its abstract, its availability statements) are not part of it; versions that changed only those are not listed.

Version 2, 28 September 2026

  • Publisher: n/a → Springer Science+Business Media

Version 1, 27 September 2026: the first record

Recorded: type, language, journal, volume, issue, pages, dates, 10 authors, 6 keywords, 9 MeSH terms, 3 funders, 80 references.

Cite

This paper

Rech, T. d. S. T., Castro, E. T., Paim, M. P., Strelow, D. N., Neto, J. S. S., Blödorn, G. B., Alves, D., Rosa, S. G., Brüning, C. A., & Bortolatto, C. F. (2026). 2-Phenyl-3-(Phenylselanyl)Benzofuran As a Promising Antidepressant Candidate: Mechanistic Insights Into Nitrergic Modulation and Subchronic Efficacy and Safety Profiling. Molecular neurobiology, 63(1), 771. https://doi.org/10.1007/s12035-026-06058-6

BibTeX

@article{rech20262,
author = {Rech, Taís da Silva Teixeira and Castro, Ediandra Tissot and Paim, Mariana Parron and Strelow, Dianer Nornberg and Neto, José Sebastião Santos and Blödorn, Gustavo Bierhals and Alves, Diego and Rosa, Suzan Gonçalves and Brüning, César Augusto and Bortolatto, Cristiani Folharini},
title = {{2-Phenyl-3-(Phenylselanyl)Benzofuran As a Promising Antidepressant Candidate: Mechanistic Insights Into Nitrergic Modulation and Subchronic Efficacy and Safety Profiling}},
journal = {Molecular neurobiology},
year = {2026},
month = jul,
volume = {63},
number = {1},
pages = {771},
publisher = {Springer Science+Business Media},
issn = {0893-7648},
doi = {10.1007/s12035-026-06058-6},
url = {https://doi.org/10.1007/s12035-026-06058-6},
pmid = {42461353},
pmcid = {PMC13375843}
}

RIS

TY - JOUR
AU - Rech, Taís da Silva Teixeira
AU - Castro, Ediandra Tissot
AU - Paim, Mariana Parron
AU - Strelow, Dianer Nornberg
AU - Neto, José Sebastião Santos
AU - Blödorn, Gustavo Bierhals
AU - Alves, Diego
AU - Rosa, Suzan Gonçalves
AU - Brüning, César Augusto
AU - Bortolatto, Cristiani Folharini
TI - 2-Phenyl-3-(Phenylselanyl)Benzofuran As a Promising Antidepressant Candidate: Mechanistic Insights Into Nitrergic Modulation and Subchronic Efficacy and Safety Profiling
T2 - Molecular neurobiology
J2 - Mol Neurobiol
PY - 2026
DA - 2026/07/16
VL - 63
IS - 1
SP - 771
SN - 0893-7648
PB - Springer Science+Business Media
DO - 10.1007/s12035-026-06058-6
UR - https://doi.org/10.1007/s12035-026-06058-6
LA - en
ER -

CSL-JSON

{
"id": "10.1007/s12035-026-06058-6",
"type": "article-journal",
"title": "2-Phenyl-3-(Phenylselanyl)Benzofuran As a Promising Antidepressant Candidate: Mechanistic Insights Into Nitrergic Modulation and Subchronic Efficacy and Safety Profiling",
"container-title": "Molecular neurobiology",
"author": [
{
"family": "Rech",
"given": "Taís da Silva Teixeira"
},
{
"family": "Castro",
"given": "Ediandra Tissot"
},
{
"family": "Paim",
"given": "Mariana Parron"
},
{
"family": "Strelow",
"given": "Dianer Nornberg"
},
{
"family": "Neto",
"given": "José Sebastião Santos"
},
{
"family": "Blödorn",
"given": "Gustavo Bierhals"
},
{
"family": "Alves",
"given": "Diego"
},
{
"family": "Rosa",
"given": "Suzan Gonçalves"
},
{
"family": "Brüning",
"given": "César Augusto"
},
{
"family": "Bortolatto",
"given": "Cristiani Folharini"
}
],
"container-title-short": "Mol Neurobiol",
"volume": "63",
"issue": "1",
"page": "771",
"DOI": "10.1007/s12035-026-06058-6",
"PMID": "42461353",
"PMCID": "PMC13375843",
"ISSN": "0893-7648",
"publisher": "Springer Science+Business Media",
"URL": "https://doi.org/10.1007/s12035-026-06058-6",
"language": "en",
"issued": {
"date-parts": [
[
2026,
7,
16
]
]
}
}

Similar papers

The papers with a page that share the most with this one: the tools found in their code, their categories, datasets, cited references and authors, the rarest counting most.

[1] doi:10.3389/fnagi.2023.1293164
A tau fragment links depressive-like behaviors and cognitive declines in Alzheimer's disease mouse models through attenuating mitochondrial function.
Journal: Frontiers in aging neuroscience
In common: pdb.org, depression, mouse
[2] doi:10.3390/ijms25137391 [code]
Novel Insights into Changes in Gene Expression within the Hypothalamus in Two Asthma Mouse Models: A Transcriptomic Lung-Brain Axis Study.
Journal: International journal of molecular sciences
In common: mouse, 3 references
[3] doi:10.1158/1535-7163.mct-25-0025
Zidesamtinib Selective Targeting of Diverse ROS1 Drug-Resistant Mutations.
Journal: Molecular cancer therapeutics
In common: pdb.org, mouse
[4] doi:10.1158/2159-8290.cd-24-0231
NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations.
Journal: Cancer discovery
In common: pdb.org, mouse
[5] doi:10.1002/pro.70332
N3A motifs in RIβ mediate allosteric crosstalk between cAMP and ATP in PKA activation.
Journal: Protein science : a publication of the Protein Society
In common: pdb.org
[6] doi:10.1186/s13041-021-00882-8
A novel red fluorescence dopamine biosensor selectively detects dopamine in the presence of norepinephrine in vitro.
Journal: Molecular brain
In common: pdb.org
[7] doi:10.1038/s41380-025-02897-2
Resting-state fMRI reveals altered functional connectivity associated with resilience and susceptibility to chronic social defeat stress in mouse brain.
Journal: Molecular psychiatry
In common: depression, mouse, 2 references
[8] doi:10.3389/fphar.2024.1472468
Identification and experimental validation of hub genes underlying depressive-like behaviors induced by chronic social defeat stress.
Journal: Frontiers in pharmacology
In common: depression, 2 references
[9] doi:10.1038/s41467-026-75697-z
Delayed astrocyte development impairs Sema6a-Plxna2/4-mediated astrocyte-neuron crosstalk and causes depressive-like behavior.
Journal: Nature communications
In common: depression, mouse, 2 references
[10] doi:10.1038/s41467-025-59115-4 [code]
Large-scale transcriptomic analyses of major depressive disorder reveal convergent dysregulation of synaptic pathways in excitatory neurons.
Journal: Nature communications
In common: depression, 2 references

Contribute

The authors of this paper can claim it, correct its record and validate its tracing map, and the maintainers of its code (its owner, or a public member of its organization) correct what it says of their repository; anyone signed in can ask for its removal. Every request goes to OSCR's own machine, which answers it; your account page follows them.

Sign in with ORCID to claim this paper as one of its authors, correct its record or validate its tracing map: when the paper's metadata lists your ORCID iD, you are recognized at once. Maintainers of its code: sign in with GitHub, then claim the repository on your account page.

Request its removal

To ask OSCR to remove this record, the copies of its authors' scripts or its tracing map, use the removal request page: signed in, you say who you are, what to remove and why, then review and confirm the request. Published rules decide every request (how).

Discussion, reproductions, activity

Discussion: code errors and mismatches between the code and the paper about this paper and its code, from readers and its authors, beside the paper and its tracing map.

Reproductions: reports from readers who ran the authors' code and did not get the paper's result, what they ran, with which environment, commit and data.

Activity: what happens around this paper: new versions of its record, its map's validation, discussions and reproductions. It opens with sign-in.